Showing results (361-370 of 392) with videos related to

Sort By:
Pageof 40
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2022
89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck CancerSarah R Verhoeff, Pim P van de Donk, Erik H J G Aarntzen, et al.
Oncotarget|August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.
Nature|October 25, 2019
Pan-cancer whole-genome analyses of metastatic solid tumoursPeter Priestley, Jonathan Baber, Martijn P Lolkema, et al.
Frontiers in Oncology|May 22, 2023
Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancerAnita J W M Brouns, Lizza E L Hendriks, Iris J Robbesom-van den Berge, et al.
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
Immunotherapy Advances|December 25, 2025
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatmentSarah R Verhoeff, Evelien A J van Genugten, Iris A E van der Hoorn, et al.
JTO Clinical and Research Reports|October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 StudyQuincy Chu, Natasha B Leighl, Veerle Surmont, et al.
The Journal of Pathology|May 15, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapyBirgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, et al.
Clinical Genitourinary Cancer|December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive MarkersSaskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Oncotarget|September 15, 2017
Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activityStanleyson V Hato, Carl G Figdor, Susumu Takahashi, et al.
Pageof 40